BioNTech and Pfizer signed contracts to supply 300 million doses of a SARS-CoV-2 vaccine for the EU,[12] 30 million doses for the United Kingdom,[13][14] 100 million doses for the United States[15] and 120 million doses for Japan,[16] if proven safe.